For those investors who missed our special online webinar yesterday with CEO Dr Daniel Tillett and Principal Scientist Dr Rodney Cusack, you can access a recording in the link below.

The webinar includes a presentation that provides a comprehensive overview of Race’s clinical program update, with two new clinical trials planned in the areas of Acute Myeloid Leukemia (AML) and Non-Small Cell Lung Cancer (NSCLC). The webinar also includes a Q&A session following the presentation.

In his closing remarks about Race Oncology, Dr Tillett said: “It’s a rare team with a rare drug and I think we are going to do something amazing.”